Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with NADPH-P450 reductase expressed in Escherichia coli

Journal of Industrial Microbiology and Biotechnology

Volumn 32, Issue 2, 2005, Pages 67-74

  Vail, Robert B ^a   Homann, Michael J ^a   Hanna, Imad ^b   Zaks, Aleksey ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

4 Hydroxydiclofenac; 6 Hydroxytestosterone; Acetaminophen; Cytochrome P450s (3A4, 2C9, 1A2); Metabolite generation

Indexed keywords

4' HYDROXYDICLOFENAC; 6BETA HYDROXYTESTOSTERONE; ANABOLIC AGENT; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DICLOFENAC; DRUG METABOLITE; PARACETAMOL; PHENACETIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL CELL; BIOTRANSFORMATION; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME ACTIVITY; ESCHERICHIA COLI; FERMENTATION; NONHUMAN; PH; PROTEIN EXPRESSION; TEMPERATURE DEPENDENCE;

ACETAMINOPHEN; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CLONING, MOLECULAR; CULTURE MEDIA; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; DICLOFENAC; ESCHERICHIA COLI; FERMENTATION; GLYCEROL; HYDROXYTESTOSTERONES; NADPH-FERRIHEMOPROTEIN REDUCTASE; OXYGEN; PHARMACEUTICAL PREPARATIONS; PHENACETIN; RECOMBINANT PROTEINS; TEMPERATURE; TESTOSTERONE;

EID: 17644376530     PISSN: 13675435     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10295-004-0202-1     Document Type: Article

References (26)

1. Blake JAR, Pritchard M, Ding S, Smith GCM, Burchell B, Wolf CR, Friedberg T (1996) Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli. FEBS Lett 397:210-214
2. Dong J, Porter TD (1996) Coexpression of mammalian cytochrome P450 and reductase in Escherichia coli. Arch Biochem Biophys 327:254-259
3. Friedberg T, Pritchard MP, Bandera M, Hanlon SP, Yao D, McLaughlin LA, Ding S, Burchell B, Wolf CR (1999) Merits and limitations of recombinant models for the study of human P450-mediated drug metabolism and toxicity: an intralaboratory comparison. Drug Metab Rev 31:523-544
4. Gillam EMJ (1998) Human cytochrome P450 enzymes expressed in bacteria: reagents to probe molecular interactions in toxicology. Clin Exp Pharmacol Physiol 25:877-886
5. Guengerich FP (2000) Pharmacogenomics of cytochrome P450 and other enzymes involved in biotransformation of xenobiotics. Drug Dev Res 49:4-16
6. Guengerich FP (2001) Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14:611-650
7. Guengerich FP (2001) Uncommon P450-catalyzed reactions. Curr Drug Metab 2:93-115
8. Guengerich FP (2002) Cytochrome P450 enzymes in the generation of commercial products. Nat Rev Drug Discov 1:359-366
9. Guengerich FP (2003) Cytochromes P450, drugs, and diseases. Mol Interventions 3:194-204
10. Hanna IH, Reed JR, Guengerich FP, Hollenberg PF (2000) Expression of human cytochrome P 450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver. Arch Biochem Biophys 376:206-216
11. Hayes AW (ed) (2001) Principles and methods of toxicology, 4th edn. Raven Press, New York
12. Iwata H, Fujita K-I, Kushida H, Suzuki A, Konno Y, Nakamura K, Fujino A, Kamataki T (1998) High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Biochem Pharmacol 55:1315-1325
13. Johnson EF, Waterman MR (eds) (1996) Methods in enzymology, vol 272. Cytochrome P450 (part B). Academic, San Diego
14. Kagawa N, Cao Q (2001) Osmotic stress induced by carbohydrates enhances expression of foreign proteins in Escherichia coli. Arch Biochem Biophys 393:290-296
15. Kanamori Y, Fujita K-I, Nakayama K, Kawai H, Kamataki T (2003) Large-scale production of genetically engineered CYP3A4 in E. coli: application of a jar-fermentor. Drug Metab Pharmacokinet 18:42-47
16. Korzekwa KR, Jones JP (1993) Predicting the cytochrome P450 mediated metabolism of xenobiotics. Pharmacogenetics 3:1-18
17. Kusano K, Waterman MR, Sakaguchi M, Omura T, Kagawa N (1999) Protein synthesis inhibitors and ethanol selectively enhance heterologous expression of P450s and related proteins in Escherichia coli. Arch Biochem Biophys 367:129-136
18. Nelson DR (2003) Comparison of P450s from human and fugu: 420 million years of vertebrate P450 evolution. Arch Biochem Biophys 409:18-24
19. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42
20. Omura T, Sato R (1964) Carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378
21. Omura T, Takesue S (1970) New method for simultaneous purification of cytochrome b5 and NADPH-cytochrome c reductase from rat liver microsomes. J Biochem (Tokyo) 67:249-257
22. Ortiz de Montellano PR (ed) (1995) Cytochrome P-450: structure, mechanism, and biochemistry, 2nd edn. Plenum, London
23. ParikhA, Gillam EMJ, Guengerich FP (1997) Drug metabolism by Escherichia coli expressing human cytochromes P450. Nat Biotechnol 15:784-788
24. Porter TD, Chang S (1999) Strategies to enhance the coexpression of cytochrome P450 2E1 and reductase in bacteria. Drug Metab Rev 31:159-174
25. Rushmore TH, Reider PJ, Slaughter D, Assang C, Shou M (2000) Bioreactor systems in drug metabolism: synthesis of cytochrome P450-generated metabolites. Metab Eng 2:115-125
26. Yasukochi Y, Masters BSS (1976) Some properties of a detergent- solubilized NADPH-cytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography. J Biol Chem 251:5337-5344